- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04540380
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
April 2, 2024 updated by: Tatsuo Kawai, MD, PhD, Massachusetts General Hospital
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tatsuo Kawai, MD PhD
- Phone Number: 617-726-0289
- Email: tkawai@mgh.harvard.edu
Study Contact Backup
- Name: Gabe Impreso Baysa, BS
- Phone Number: 617-643-7569
- Email: gimpresobaysa@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Tatsuo Kawai, MD, PhD
- Phone Number: 617-726-0289
- Email: tkawai@partners.org
-
Principal Investigator:
- Tatsuo Kawai, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female 18-60 years of age.
- Candidate for a living-donor renal allograft from an HLA mismatched donor
- Subjects with chronic kidney disease stage or ESRD who are treated with either hemodialysis or peritoneal dialysis.
- First transplant.
- Use of FDA-approved methods of contraception
- Ability to understand and provide informed consent.
- Negative COVID at screening and 2 days before procedure
Exclusion Criteria:
- ABO blood group-incompatible renal allograft.
- Participant with a (non DSA) PRA > 20% within 6 months prior to transplant
- Persistent Leukopenia (WBC less than 2,000/mm3) or thrombocytopenia (<100,000/mm3).
- Seropositivity for HIV-1, hepatitis B core antigen, or hepatitis C virus (confirmed by hepatitis C virus RNA); or positivity for hepatitis B surface antigen.
- Active infection
- Left ventricular ejection fraction < 40% as determined by TTE or clinical evidence of heart failure
- Forced expiratory volume FEV1 or DLCO < 50% of predicted.
- Lactation or pregnancy
- History of cancer
- Underlying renal disease etiology with a high risk of disease recurrence in the transplanted kidney (such as focal segmental glomerulosclerosis).
- Prior dose-limiting radiation therapy
- Known genetic disease or family history that may result in greater sensitivity to the effects of irradiation, or a physical deformity that would preclude adequate shielding or appropriate dosing during the irradiation component of the conditioning regimen
- Enrollment in other investigational drug studies within 30 days prior to enrollment
- Abnormal (>2 times lab normal) values for (a) liver function chemistries (ALT, AST, AP), (b) bilirubin, (c) coagulation studies (PT, PTT).
- Allergy or sensitivity to any component of Siplizumab, Fludarabine, Cyclophosphamide, tacrolimus, DMSO, MMF or rituximab.
- The presence of any medical condition that the investigator deems incompatible with participation in the trial.
- Subjects who have non-insulin dependent diabetes (NIDDM) without good blood glucose control (HbA1c<7). Subject with severe retinopathy, gastroparesis, or severe neuropathy which prevent subject's normal independent daily activities will be excluded from the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Transient Chimerism
Time Frame: 36 months after immunosuppression withdrawal
|
36 months after immunosuppression withdrawal
|
Incidence of Chimerism Transition Syndrome
Time Frame: 36 months after immunosuppression withdrawal
|
36 months after immunosuppression withdrawal
|
Incidence of tolerance induction
Time Frame: 36 months after immunosuppression withdrawal
|
36 months after immunosuppression withdrawal
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2021
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
August 18, 2020
First Submitted That Met QC Criteria
September 1, 2020
First Posted (Actual)
September 7, 2020
Study Record Updates
Last Update Posted (Actual)
April 3, 2024
Last Update Submitted That Met QC Criteria
April 2, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Renal Insufficiency
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Cyclophosphamide
- Rituximab
- Fludarabine
Other Study ID Numbers
- Tolerance SMC-MGH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
University Hospital, Clermont-FerrandRecruitingAcute Kidney Injury | Transient Acute Renal Failure | Persistent Acute Renal FailureFrance
-
University Hospital, GhentCompletedAcute Renal Failure | Chronic Renal FailureBelgium
-
The University of Hong KongHospital Authority, Hong KongCompletedEnd-stage Renal Failure (ESRF)Hong Kong
-
Washington University School of MedicineCompletedAcute Renal Failure | Chronic Renal FailureUnited States
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
Clinical Trials on Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab
-
Massachusetts General HospitalCompleted
-
Masonic Cancer Center, University of MinnesotaTerminated
-
Gruppo Italiano Studio LinfomiCompleted
-
Massachusetts General HospitalOssium Health, Inc.; ITB-Med LLCRecruitingKidney Failure | Kidney Transplant; Complications | ChimeraUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Failure, Chronic | Kidney TransplantationUnited States
-
Massachusetts General HospitalTerminatedMultiple Myeloma | Hodgkin Disease | Non Hodgkin's LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed
-
German CLL Study GroupTerminatedProlymphocytic LeukemiaGermany
-
Institute of Cancer Research, United KingdomAustralasian Leukaemia and Lymphoma GroupCompletedLymphomaAustralia, United Kingdom
-
Hoffmann-La RocheCompleted